TD Cowen Downgrades Bio-Techne to Hold
TD Cowen lowered Bio-Techne's rating to hold with a $73 price target, a 3.33% upside from the current price.
Key Points
- TD Cowen downgraded Bio-Techne Corporation to a hold rating with a $73 price target on June 30, 2026.
- TD Cowen's $73 price target implies 3.33% upside from Bio-Techne Corporation's ($TECH) current $70.65 share price.
- Shares of Bio-Techne traded near $70.9 on Tuesday, with a market cap of about $11.06 billion and a P/E ratio of 101.4.
- Analysts' consensus recommends buying, with an average target price of $67.92 across 13 opinions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, TD Cowen analyst Kyle Boucher downgraded Bio-Techne Corporation (NasdaqGS:TECH) to a hold rating, setting a price target of $73. This update reflects a more cautious outlook on the biotechnology firm.
TD Cowen vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Bio-Techne Corporation Stock Down 2.3%
Shares of Bio-Techne Corporation traded near $70.9 on Tuesday. The company has a market cap of about $11.06 billion and a P/E ratio of 101.4, with a forward P/E of 34.7. Bio-Techne's stock has seen a 52-week low of $43.2 and a high of $72.16. The stock's 50-day moving average is $53.02, and its 200-day moving average is $57.70. The company has a current ratio of 4.49 and a quick ratio of 2.80, indicating solid liquidity.
$TECH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Bio-Techne reported revenue of $1.21 billion, though it experienced a slight decline with a revenue growth rate of -1.5%. The company's net margin stands at 9.0%, and its return on equity is 5.3%. The next earnings report is expected on August 5, 2026.
Dividend
Bio-Techne offers an annual dividend rate of $0.32, yielding 0.45% with a payout ratio of 45.71%.
Insider Buying and Selling at Bio-Techne Corporation
On June 2, 2026, Steven Crouse, President of Diagnostics and Spatial Biology, sold 600 shares and later bought 600 shares. Additionally, Amy Herr acquired 6,636 shares on May 8, 2026, at an average price of $47.60.
Analysts Set New Price Targets
On June 30, 2026, TD Cowen downgraded Bio-Techne to a hold rating with a $73 price target. Other firms such as Citigroup and Stephens & Co. also downgraded their ratings to hold with the same price target. The consensus among 13 analysts recommends buying, with an average target price of $67.92.
About Bio-Techne Corporation
Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, develops and sells life science reagents, instruments, and services globally. The company operates through its Protein Sciences and Diagnostics and Spatial Biology segments. It provides products for research, diagnostics, and bioprocessing markets, including cytokines, antibodies, and diagnostic assays. Led by CEO Kim Kelderman, Bio-Techne employs around 3,100 people.
Bottom Line
TD Cowen's downgrade of Bio-Techne to a hold rating signals a more cautious approach to the company's prospects. Investors may find the stock's current valuation and liquidity ratios of interest. As a reminder, analyst ratings reflect opinions at the time of the report and may not capture future developments.
Get Bio-Techne Corporation alerts
New 13F filings, insider trades, and analyst moves on $TECH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.